A Multicenter, Single-arm, Open-label Study to Investigate the Efficacy and Safety of Yimitasvir Phosphate (DAG181)/Sofosbuvir(SOF) Combination for 12 Weeks in Subjects With Chronic Genotype 1 HCV Infection
Phase of Trial: Phase III
Latest Information Update: 05 Aug 2019
Price : $35 *
At a glance
- Drugs Sofosbuvir (Primary) ; Yimitasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Sunshine Lake Pharma
- 01 Aug 2019 Status changed from active, no longer recruiting to completed.
- 08 Apr 2019 Status changed from not yet recruiting to active, no longer recruiting.
- 05 Apr 2018 New trial record